Justice Department Recovers $3.8 Billion from False Claims Act Cases in Fiscal Year 2013

DOJ press release (20 Dec 2013) on FY2013 FCA recoveries: $3.8 billion (second largest); $17 billion since January 2009 ("nearly half" since 1986, words); health care $2.6 billion, $12.1 billion since January 2009; drugs and devices $1.8 billion; state Medicaid $443 million; procurement record $890 million (also "more than $887 million" in the procurement section); relator up to 30%; 752 qui tam suits (433 in FY2009; "three to four hundred" 2000-2009, words); qui tam recoveries $2.9 billion, $13.4 billion since January 2009; whistleblower awards $345 million, $1.98 billion since January 2009; named matters Abbott $1.5 billion ($575 million federal civil, $225 million state, nearly $700 million criminal), Amgen $762 million ($598.5 million FCA), Ranbaxy $505 million ($237 million federal), Tuomey $237 million judgment, Wasserman $26.3 million (and Tampa Pathology $950,000), UTC $664 million judgment, W.W. Grainger $70 million, RPM/Tremco $61 million, Toyo Ink $45 million, Education Holdings $10 million: none linked to a qui tam suit or relator in this release, so not cases. Out of scope: FDCA criminal results (16 convictions, more than $1.3 billion). Already in the data: 8 observations. Added: 1 rule, 6 observations. Decision 10 pass (2026-10-10): every named settlement, judgment and newly announced government suit not already in cases.csv added as a case with whistleblower_link=not_stated (the document does not tie it to a whistleblower): 11 cases (9 settlements, 2 judgments (outcome 'reported')). Amounts as printed (lower/upper bounds and global vs civil parts explained in notes); individuals only where named by the agency as parties.